



























Cancer is a complex disease against which mammals 
have developed multiple protective mechanisms. Late-
stage cancer is almost invariably accompanied by 
metastasis, accounting for the most common cause of 
death of cancer patients. The metastatic cascade 
comprises several steps, ultimately leading to the 
emergence of secondary tumors at distant sites from the 
primary lesions [1]. One process contributing to the first 
phase of metastasis is the epithelial-mesenchymal 
transition (EMT). EMT is well known for its important 
roles in embryogenesis and development, in which 
epithelial cells acquire properties reminiscent of those 
of mesenchymal cells. Full differentiation and the 
establishment of a specific tissue architecture may 
involve several rounds of EMT, but also of the reverse 
process, mesenchymal-epithelial transition (MET) [2].  
 
EMT is accompanied by the loss of the cell-cell 
contacts so typical of epithelial cells, and the acquisition 
of migratory and motile properties. It is for these 
reasons that EMT can have adverse effects to the 
organism, contributing to pathological processes such as 
fibrosis and cancer [3]. In particular, when adopted by 
cancer cells, EMT allows for the invasion and 
intravasation of tumor cells into surrounding tissues, 
blood and lymphatic circulation [4, 5].  Similar to its  
 
 
























physiological role, also in metastasis EMT conceivably 
corresponds to a transient and dynamic process, which 
involves several steps. Furthermore, it does not appear 
to occur in the bulk of the tumor cells but rather locally, 
at the invasive fronts of a tumor [6-8]. 
 
Epithelia are formed by polarized layers of epithelial 
cells, which are tightly connected by adherens 
junctions. These consist of E-cadherin, α-,  β- and γ-
catenin and are connected to the actin cytoskeleton, thus 
providing the cells with a rigid structure. During EMT, 
several epithelial proteins, like E-cadherin, α-, β- and γ-
catenin are downregulated, whereas mesenchymal 
proteins, including vimentin, fibronectin and smooth 
muscle actin, can be upregulated [9]. The most common 
characteristic of EMT is the downregulation of E-
cadherin. This glycoprotein can be repressed by two 
types of transcription factors, basic helix-loop-helix 
transcription factors including E12/E47, Twist1 (Twist) 
and Twist2 (Dermo1), and the zinc finger transcription 
factors, including the Snail family (Snail or Snai1 and 
Slug or Snai2), and the Zeb family, comprising Zeb1 
and Zeb2 (also called SIP1) [10-16]. These transcription 
factors bind to E-boxes within the CDH1 promoter and 
thereby suppress its transcription. Most of these factors 
have been demonstrated to play a critical role in 
invasion and metastasis [11, 16-19]. EMT can be 

















to  contribute  to  cancer  progression.  Conversely,  cellular  senescence  constitutes  a  failsafe  program  against  cancer
progression. Interestingly, EMT and senescence seem to cross paths, with several factors playing dominant roles in both
settings. Here, we describe recent observations that link these important cellular processes.  
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effectors including the PI3 and MAP kinases, but also 
the Wnt, Notch and NFkB pathways, all of which are 




Another mechanism involved in cancer progression is 
cellular senescence. Senescent cells fail to proliferate, but 
remain metabolically active. Senescence can be triggered 
by short or malfunctioning telomeres (called replicative 
senescence), but also prematurely, by a variety of stress 
signals, including unscheduled oncogenic signaling [27, 
28]. “Oncogene-induced senescence” (OIS), as the latter 
phenomenon is called, relies on the activation of tumor 
suppressor gene networks often comprising RB and p53, 
mediating cell cycle arrest [29]. In addition to elevated 
tumor suppressor signaling, OIS is associated with 
several other hallmarks, including increased activity of 
lysosomal  β-galactosidase (SA-β-GAL), chromatin 
remodeling and induction of DNA damage [30]. In many 
settings, OIS is associated with the secretion of dozens of 
cytokines, comprising the “Senescence-Messaging 
Secretome”, or SMS, denoting its communicative role 
[31]. Cellular senescence can be triggered not only by 
oncogene activation, but also by the loss of tumor 
suppressor genes, including PTEN, NF1 and RB [32]. 
 
Although OIS has long been viewed as an exclusive in 
vitro phenomenon, it is being increasingly recognized as 
a critical feature of mammalian cells to suppress 
tumorigenesis, acting alongside cell death programs like 
apoptosis. For example, human melanocytic nevi 
(moles), benign tumors that have a low propensity to 
progress towards melanoma, display several hallmarks 
of OIS. In addition to harboring an oncogenic mutation 
(most commonly BRAF
E600), they display little 
proliferative activity, a characteristic that is typically 
maintained for decades. Furthermore, nevi express 
elevated levels of p16
INK4A and have increased SA-β-
GAL activity [33, 34]. Similar results have recently 
been reported for BRAF
E600 knockin mice in which the 
activated kinase is expressed selectively in the 
melanocytic compartment [35, 36]. Several additional 
mouse models have also shown senescence biomarkers 
in early neoplastic lesions [37]. For example, lung 
adenomas expressing oncogenic RAS
V12 are in a 
senescent state in contrast to invasive adenocarcinomas 
that are proliferating [38]. 
 
EMT players regulating senescence 
 
For almost two decades, the transcription factor Twist 
has been known for its important role in embryonic 
development [39]. More recently, Twist, but also other 
EMT regulators, have attracted considerable attention 
for their contribution to cancer progression. For 
example, Weinberg and co-workers found that Twist 
induces EMT and, as such, plays a critical role in 
metastasis [11]. Other transcription factors from the 
Snail and Zeb family are endowed with similar 
capacities [40]. Earlier, a role for Twist 1 and 2 in 
apoptosis was revealed in an expression library screen 
for cDNAs suppressing the pro-apoptotic effect of the 
myc oncogene in MEFs [41]. In that setting, Twist 
reverts p53-induced cell cycle arrest and suppresses Arf, 
a gene that is highly induced during cellular and 
oncogene-induced senescence [42, 43]. Similarly, in 
human prostate epithelial cells, Twist bypasses cellular 
senescence in an p14
ARF-dependent fashion [44]. 
Conversely, RNAi depletion of Twist induces cell cycle 
arrest in gastric cancer cells, which correlates with 
regulation of the major ARF effector, p53 [45].  
 
Further mechanistic insight into how Twist impacts on 
the cell cycle machinery has evolved. Twist over-
expression prevents the upregulation of p21
CIP1 and p53 
upon genotoxic stress in several cell lines [46-48]. In 
addition to indirect regulation through ARF, Twist may 
regulate p53 by a direct interaction, thereby preventing 
it from binding to DNA [49]. Consistent with this, 
adriamycin treatment leads to increased levels of a 
protein complex comprising p53, MDM2 and Twist 
[47]. A search for upstream targets revealed that 
PKB/AKT can phosphorylate Twist at Ser42, inhibiting 
p53 activity in response to γ-irradiation and promoting 
cell cycle progression [48]. Ansieau et al. showed that 
Twist affects the transcriptional regulation of p16
INK4A 
and p21
CIP1 [50], arguing together with previous 
publications that Twist can simultaneously deregulate 
the p53 and RB pathways, both of which affect several 
processes, including senescence. The signaling 
pathways targeted by Twist may even go beyond this, as 
suggested by the observation that Twist enhances the 
transforming activity of N-MYC in Ink4a-ARF
-/- MEFs 
[46]. Twist can also augment the transforming effects of 
E1A and Ras
V12 [41], although it remains to be seen 
whether Twist acts in such contexts during human 
tumor progression [51]. 
 
Extending these findings, increasing evidence suggests 
that the two processes that seem to operate 
independently, EMT and senescence, are in fact 
intertwined. For example, while RAS
V12 induces EMT 
in epithelial cells, often in a cooperative fashion with 
TGFβ [20], it also induces senescence in human diploid 
fibroblasts [27]. Puisieux and co-workers showed that 
whereas ectopically expressed ErbB2 induces 
senescence, overexpression of both Twist and ErbB2 
triggers EMT and allows for senescence bypass, both in 
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with the prevailing view that a single oncogene is 
insufficient to drive cancer progression: it commonly 
acts cytostatically or induces a death program and 
requires a collaborating oncogene to convert this into a 
pro-survival and mitogenic process [37]. But more 
importantly, the studies mentioned above, and several 
that will be discussed below, have provided a link 
between EMT and cellular senescence.  
 
The premise that activation of EMT is linked to 
suppression of cellular senescence has been proposed 
also in the context of another EMT regulator, Zeb1 [52]. 
Specifically, depletion of Zeb1 in MEFs causes MET, 
which is characterized by increased expression of 
epithelial proteins such as E-cadherin and decreased 
expression of mesenchymal proteins. Zeb1 loss triggers 
premature senescence by binding directly to the 
CDKN1A and INK4B promoters, thereby 
simultaneously affecting p53 and RB signaling. In turn, 
Zeb1 is regulated via the Zeb1/miR200 feedback loop, 
which is thought to drive cancer progression via 
promoting EMT and inhibiting senescence [53]. 
 
These findings prompt several interesting questions. 
Probably most importantly, does the coordinated 
deregulation of EMT and senescence reflect only a 
“collateral effect”, or instead, are there mechanistic 
links that tie these two processes together [54]? A 
recent study suggests the latter possibility [55]. 
Esophageal squamous cell carcinoma cells expressing 
activated EGFR were shown to undergo premature 
senescence. A subpopulation of cells emerged from this 
pool, which expressed elevated levels of Zeb1 and 2, as 
if these factors suppressed the senescence program. 
Interestingly, when cells were locked in a senescent 
state by activation of p53, the cytokine TGFβ was no 
longer able to induce EMT, raising the possibility that 
senescent cells cannot undergo EMT. This is in line 
with the findings of Ansieau et al. that senescence 
abrogation is accompanied by an EMT [56]. 
 
Although a general role for other EMT-associated 
transcription factors in senescence remains to be 
elucidated, some can regulate several cell cycle 
regulators that have also been implicated in senescence. 
For example, in MDCK canine epithelial cells, Snail 
deregulates the cell cycle machinery by induction of 
p21
CIP1 and reduction of cyclin D1 and D2, thereby 
effectively inducing cell cycle arrest [57]. Also in 
HEPG2 cells, Snail induces cell cycle arrest via 
regulation of p15
INK4B [58], a relative of p16
INK4A that 
has also been associated with senescence [59]. 
Conversely, in combination with an oncogene, Snail can 
have the opposite effect, for example by inhibiting 
E2A-induced p21
CIP induction [60]. Furthermore, Snail 
can suppress p53 by direct binding, at least in certain 
settings [61, 62]. Overexpression of another 
transcription factor, Zeb2, reduces the proliferative 
capacity of cells, involving inhibition of cyclin D1 [63]. 
However, although from these results it appears that 
EMT-associated transcription factors can regulate the 
cell cycle through proteins that are also involved in 
senescence, it remains to be established whether these 































Senescence players regulating EMT 
 
Whereas several prototypic EMT regulators have been 
implicated in senescence, conversely, a number of key 
senescence players have been found to affect EMT. For 
example, the viral oncoprotein SV40 LT, which 
simultaneously deregulates the cell cycle regulators p53 
and RB, can suppress E-cadherin to induce a 
mesenchymal-like morphology. This is dependent on 
the downregulation of RB [64]. As RB was recently 
demonstrated to play a unique role, among the pocket 
protein family, in cellular senescence [65], these 
findings may link RB, senescence and EMT. Also in 
another setting, when EMT is induced by TGFβ/TNFα 
in MCF10A cells, RB is downregulated. Furthermore, 
Figure 1. Working model schematically depicting how 
EMT  and  senescence  are  linked  and  contribute  to 




by  simultaneously  inhibiting  oncogene‐induced 
senescence and promoting EMT. 
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morphological effect and the suppression of E-cadherin 
expression [66], downregulation of RB induces EMT 
[67]. In both cases this is regulated by binding of RB to 
the  CDH1 promoter, thereby suppressing its 
transcription [66, 67]. A link between RB and E-
cadherin was also described in a slightly different 
setting: E-cadherin-mediated aggregation prevents cell 
death induced by active PKC. This is accompanied by 
RB activation, cell cycle arrest and survival [68]. 
 
Wild type p53, a key senescence player [28], inhibits 
the transcription factor Slug (or Snai2) via MDM2, 
whereas mutant p53 stabilizes Slug, thereby increasing 
its levels and enhancing cancer cell invasiveness [69]. 
In non-small-cell lung cancer, where p53 is often 
mutated, Slug expression is high, correlating with low 
MDM2 levels and lower overall survival.  
 
Another factor that can be associated with cellular 
senescence and has also been implicated in EMT is 
p21
CIP1. It was shown that p21
CIP1 is inhibited during 
Ras
V12-induced EMT in MCF10A cells. Furthermore, 
whereas transgenic mice expressing Ras
V12 display only 
some features of EMT, compound transgenic mice with 
a deficiency for p21
CIP1 show accelerated mammary 
tumor formation, which may result from the induction 
of more extensive EMT features [70]. This suggests that 
p21
CIP1 plays a role in EMT both not only in vitro but 
also in vivo. But again, to what extent this CKI causally 
connects senescence and EMT remains to be seen. 
 
The inflammatory protein network seems to represent 
yet another link between EMT and senescence. It has 
recently been shown that OIS is accompanied by the 
induction of several interleukins, revealing that 
senescence is commonly associated with a robust 
inflammatory response [31, 71, 72, 73]. Unexpectedly, 
OIS can be abrogated (or even reverted) by 
downregulation of either interleukin 6 (IL-6) or IL-8 
[71]. The latter is specifically co-expressed with 
p16
INK4A-positive non-proliferating cells in colon 
adenomas, suggesting that some interleukins contribute 
to tumor suppression in benign human lesions [71]. 
Similarly, silencing of a chemokine receptor, CXCR2, 
results in bypass from senescence [72]. On the other 
hand, IL-6 is able to induce EMT in epithelial cells, 
suggesting that interleukins also participate in the 
regulation of EMT [74]. Furthermore, EGF-induced 
EMT in ovarian carcinoma cells induces both IL-6 
expression and secretion [75]. Also IL-8 is associated 
with EMT: it is induced in cells undergoing TGFβ-
induced EMT [76]. Interestingly, CXCR1 (but not 
CXCR2) is also induced in these cells. The 
interleukin-related protein ILEI was shown to be 
important for EMT and metastasis [77]. These 
observations suggest that the inflammatory network is 




Recent observations suggest that two important 
processes involved in cancer progression, senescence 
and EMT, are crossing paths. For example, several 
transcription factors can both inhibit senescence and 
induce EMT (Figure 1). In doing so, they seem to have 
a double role in promoting cancer: while an override of 
the senescence program contributes to the acquisition of 
indefinite proliferative capacity, induction of EMT 
bypasses rate-limiting aspects of the metastatic cascade. 
Conversely, at least in theory, this may open new 
strategic therapeutic avenues that, by targeting the 
major players promoting EMT and senescence, have a 
double impact. This potential perspective not 
withstanding, there are several important questions 
remaining. Although senescence bypass can be 
accompanied by EMT, it will be of interest to determine 
whether, in fact, EMT contributes to the override of 
senescence. Indeed, although several observations have 
revealed features of EMT in association with (abrogation 
of) cellular senescence, or vice versa, in many cases it 
remains to be established whether the processes are 
mechanistically tied together. For example, is there a 
direct role for E-cadherin in the regulation of senescence? 
While Twist and other transcription factors that can 
promote EMT have multiple effector genes, also several 
senescence players, including CDKN2A, harbor E-boxes 
in their promoters [78], suggesting that the EMT-
associated transcription factors can also regulate the cell 
cycle without direct regulation of E-cadherin. Finally, it 
is interesting to note that EMT and senescence share the 
phenomenon that the biomarkers that accompany these 
processes are regulated differentially in different (genetic 
and cellular) settings, for reasons that are as yet largely 
unclear. Answers to these and related questions will not 
only increase our understanding of these two mechanisms 
driving cancer progression, but eventually also help to 
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